To Check Comparison of Apremilast and Methotrexate Efficacy in Patients With Moderate to Severe Plaque Psoriasis Presented to Tertiary Care Hospital

Sponsor
Syeda Sana Zaman
Study ID
NCT07337434
Phase
EARLY_PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Chronic Plaque Psoriasis

Eligibility Criteria

Sex
ALL
Age
18 Years - 60 Years
Healthy Volunteers
Accepted

Interventions

  • Methotrexate — DRUG
    Group A will recieve methotrexate 10-25mg once weekly for 3 months. Along with folic acid once daily except on day of methotrexate.
  • Apremilast — DRUG
    Group B will recieve tablet apremilast 30mg twice daily for 3 months.

Study Details

This study aims to compare efficacy of methotrexate vs apremilast in the management of chronic plaque psoriasis.Given the high prevalence of psoriasis in Pakistan and the significant psychological impact on patients, particularly in Peshawer,this study will provide valuable insights into optimal treatment strategies.

Key Dates

First listed
Jan 13, 2026
Start date
Dec 25, 2025
Status verified
Dec 2025
Primary completion
Jun 25, 2026
Completion
Jun 25, 2026

Study Design

Enrollment
106 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Methotrexate
    This group will recieve methotrexate 10-25mg once weekly for 3 months,
  • Experimental: Apremilast
    This group will recieve apremilast 30mg BD for 3 months.

Primary Outcome Measure

PASI SCORE calculation [ Time Frame: 3 months ]

Central Contacts